Priya Rastogi, MD discusses MonarchE: primary overall survival results of adjuvant Abemaciclib plus Endocrine therapy For HR+, HER2-, high-risk early breast cancer.
Priya Rastogi, MD
Advertisement
Articles by Priya Rastogi, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5